{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:52:32Z","timestamp":1761540752227},"reference-count":52,"publisher":"Wiley","issue":"s6","license":[{"start":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T00:00:00Z","timestamp":1163116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>Despite significant advances in the treatment of haemophilia, including availability of recombinant coagulation factor replacement products and the use of prophylactic infusion regimens, the segment of haemophilic patients who develop inhibitory antibodies remain at higher risk for morbidity and mortality associated with recurrent or uncontrolled bleeding events. Bypassing agents represent the mainstay of treatment and prevention of bleeding. The most commonly used of the currently available therapeutic agents are a plasma\u2010based therapy, factor eight inhibitor bypassing activity, vapour heated, and a recombinant therapy, NovoSeven (recombinant activated factor VIIa). A substantial body of literature exists to document efficacy and adverse event profiles for these two products. There is, however, a paucity of data arising from adequately powered prospective trials to determine optimal treatment and dosing in various clinical situations. Certain clinical circumstances, patient profiles, individual responses, or provider predilection may lead to preferential use of one of these products over the other; however, the continued presence of both agents in the therapeutic armamentarium remains critically important to this fragile population. The historical use, clinical practice concerns, published comparative studies and methods for optimization of these two bypassing agents are reviewed.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2006.01367.x","type":"journal-article","created":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T14:06:14Z","timestamp":1163167574000},"page":"54-61","source":"Crossref","is-referenced-by-count":21,"title":["An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents"],"prefix":"10.1111","volume":"12","author":[{"given":"R.","family":"MEHTA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"PARAMESWARAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. D.","family":"SHAPIRO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,11,10]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00037.x"},{"key":"e_1_2_12_3_2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1001\/jama.1969.03160100038010","article-title":"Prothrombin concentrates in treatment of Christmas disease and allied disorders","volume":"208","author":"Breen FA","year":"1969","journal-title":"JAMA"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198008213030803"},{"key":"e_1_2_12_5_2","first-page":"Abstract 295","volume-title":"\u2018\u2018Auto\u2019\u2019\u2010factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors","author":"Fekete LF"},{"key":"e_1_2_12_6_2","volume-title":"Use of animal factor VIII concentrates in patients with factor VIII inhibitors","author":"Roberts HR"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197407252910402"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109243051301"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.5.1135.1135"},{"issue":"3","key":"e_1_2_12_10_2","first-page":"3","article-title":"Thrombogenicity associated with factor IX complex concentrates","volume":"28","author":"Lusher JM","year":"1991","journal-title":"Semin Hematol"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00935.x"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656122"},{"issue":"1","key":"e_1_2_12_13_2","first-page":"Abstract P1628","article-title":"Long\u2010term prophylaxis with FEIBA? in patients with high\u2010responding inhibitors","volume":"1","author":"Ettingshausen EC","year":"2003","journal-title":"J Thromb Haemost"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20162"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30790385521.x"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00532.x"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.1.36.36"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00032.x"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110939"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90259-0"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00209.x"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199308000-00001"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.80"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615357"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"issue":"1","key":"e_1_2_12_26_2","first-page":"S61","article-title":"Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high\u2010dose activated factor VII","volume":"9","author":"Hoffman M","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01075.x"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.11.006"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-07-0510"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200004001-00010"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-16890"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.11.019"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200004001-00009"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.3.293"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00912.x"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.11.020"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00937.x"},{"key":"e_1_2_12_38_2","first-page":"240","article-title":"Acute myocardial infarction complicating therapy with fVIII followed by APCC and rFVIIa in a 26\u2010year\u2010old man with haemophilia A and fVIII inhibitor","volume":"4","author":"Juvonen E","year":"1998","journal-title":"Haemophilia"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613110"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2002.126038"},{"key":"e_1_2_12_41_2","doi-asserted-by":"crossref","first-page":"98a","DOI":"10.1182\/blood.V106.11.324.324","article-title":"The FEIBA? NovoSeven? comparative study (FENOC)\u2013A randomized evaluation of by\u2010passing agents in hemophilia complicated by inhibitors","volume":"106","author":"Berntorp E","year":"2005","journal-title":"Blood"},{"key":"e_1_2_12_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01772.x"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00925.x"},{"key":"e_1_2_12_44_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0609.1998.tb01103.x","article-title":"Early treatment with recombinant factor VIIa results in greater efficacy with less product","volume":"63","author":"Lusher JM","year":"1998","journal-title":"Eur J Haematol Suppl"},{"issue":"1","key":"e_1_2_12_45_2","first-page":"S125","article-title":"Development of anaphylactic shock in haemophilia B patients with inhibitors","volume":"9","author":"Warrier I","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199701000-00003"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70061-2"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.1115"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-8461"},{"issue":"2","key":"e_1_2_12_50_2","first-page":"37","article-title":"The economics of factor VIII inhibitor treatment","volume":"31","author":"Lipton RA","year":"1994","journal-title":"Semin Hematol"},{"key":"e_1_2_12_51_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0609.1998.tb01107.x","article-title":"Pharmaco\u2010economic aspects of inhibitor treatment","volume":"63","author":"Goudemand J","year":"1998","journal-title":"Eur J Haematol Suppl"},{"key":"e_1_2_12_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01153.x"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.429"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2006.01367.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2006.01367.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T07:17:35Z","timestamp":1707376655000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2006.01367.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,10]]},"references-count":52,"journal-issue":{"issue":"s6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1111\/j.1365-2516.2006.01367.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01367.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,10]]}}}